HARROW, INC. (HROW): Results of Operations and Financial Condition
HARROW, INC. (HROW) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.2 3 ex99-2.htm EX-99.2 Exhibit 99.2 28 th Quarterly Letter to Stockholders August 10, 2026 Dear Harrow Stockholders: The first half of 2026 was about driving demand and fine-tuning business rules ; the second half is about converting growing demand into revenue and profits
How this was made
The 30-second read
Why it matters
Traders can use the disclosed Q2 revenue, sequential growth, and reiterated full-year revenue and Adjusted EBITDA ranges to reassess second-half ramp assumptions and execution risk across VEVYE, IHEEZO, and the TYRVAYA portfolio expansion.
Market read
A primary filing with Q2 operating updates and reiterated 2026 guidance, emphasizing commercial execution catalysts and second-half ramp credibility.
What to watch
The excerpt highlights unit demand and pricing improvements but does not quantify gross-to-net, margin trajectory, or the exact timing/closing certainty for the TYRVAYA rights acquisition, which are key to validating the ramp.
Background
Harrow filed an SEC 8-K with its quarterly letter to stockholders, focusing on commercial execution and reiterating 2026 guidance.
Ticker impact
Harrow reiterates full-year 2026 guidance and reports Q2 2026 revenue of $70.7M, citing improving pricing and demand drivers.
Near-term bias to the upside if investors view the second-half ramp as credible, but the magnitude of the implied H2 acceleration raises execution risk.
This is a primary SEC filing with concrete quarterly results, guidance ranges, and specific commercial catalysts (coverage win effective Aug 1, IHEEZO net price improvement, and TYRVAYA rights acquisition referenced). However, the excerpt does not include full financial statements or consensus context, limiting precision on how much is already priced in.
Market effects
Reinforces demand and reimbursement/access dynamics in U.S. ophthalmology dry eye and retina franchises, potentially supporting sentiment for specialty pharma commercial execution.
Primarily U.S.-focused commercial execution and reimbursement changes.
Limited, as the disclosed drivers are largely U.S. market access, pricing, and product portfolio execution.
Counterpoint
The guidance implies a very large second-half revenue ramp versus first-half results, so any delay in TYRVAYA close/integration or slower prescription acceleration could pressure the stock.
Key entities
- companyHarrow, Inc.
U.S. specialty pharmaceutical company providing dry eye and retina products; subject of the 8-K quarterly letter and guidance reiteration.
- productTYRVAYA
Dry eye/ophthalmic product whose global rights acquisition is referenced as a portfolio expansion catalyst.
- productVEVYE
Dry eye product highlighted for prescription growth, market share gains, and improving gross-to-net/pricing dynamics.
- productIHEEZO
Dry eye product highlighted for net price improvement and best-ever unit demand quarter despite reimbursement headwinds.
